Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $45.00 at Jefferies Financial Group

Denali Therapeutics (NASDAQ:DNLI) had its price objective boosted by Jefferies Financial Group from $40.00 to $45.00 in a research note published on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently commented on DNLI. Wedbush dropped their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Citigroup lifted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Bank of America boosted their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.90.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded up $1.09 during mid-day trading on Friday, reaching $27.05. 837,711 shares of the company’s stock were exchanged, compared to its average volume of 1,078,313. The firm has a 50-day moving average price of $27.38 and a two-hundred day moving average price of $23.07. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of -9.49 and a beta of 1.38. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same quarter in the previous year, the firm earned $1.30 earnings per share. The firm’s revenue was down 99.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Denali Therapeutics will post -2.53 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the last quarter. SG Americas Securities LLC bought a new stake in Denali Therapeutics during the first quarter worth about $147,000. ClariVest Asset Management LLC lifted its stake in Denali Therapeutics by 18.8% during the first quarter. ClariVest Asset Management LLC now owns 47,748 shares of the company’s stock worth $980,000 after purchasing an additional 7,568 shares during the last quarter. Swiss National Bank lifted its stake in Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Denali Therapeutics during the first quarter worth about $4,330,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.